Protective Effects and Mechanisms of Shenhua Tablet () on Toll-Like Receptors in Rat Model of Renal Ischemia-Reperfusion Injury.
10.1007/s11655-017-2756-6
- Author:
Qing-Ping LI
1
;
Ri-Bao WEI
2
;
Xi YANG
1
;
Xiao-Yong ZHENG
1
;
Ting-Yu SU
1
;
Meng-Jie HUANG
1
;
Zhong YIN
1
;
Xiang-Mei CHEN
1
Author Information
1. Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, 100853, China.
2. Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, 100853, China. wrbbj2006@126.com.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Shenhua Tablet;
ischemia-reperfusion injury;
kidney injury;
myeloid differentiation factor 88;
toll-like receptors
- MeSH:
Animals;
Disease Models, Animal;
Drugs, Chinese Herbal;
pharmacology;
Kidney;
blood supply;
drug effects;
Male;
Myeloid Differentiation Factor 88;
analysis;
genetics;
Rats;
Rats, Wistar;
Reperfusion Injury;
physiopathology;
prevention & control;
Signal Transduction;
drug effects;
Tablets;
Toll-Like Receptors;
analysis;
drug effects;
genetics
- From:
Chinese journal of integrative medicine
2019;25(1):37-44
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To investigate the protective effects and potential mechanisms of Shenhua Tablet (, SHT) on the toll-like receptors (TLRs)-mediated signaling pathways in a rat model of kidney ischemia-reperfusion injury (IRI).
METHODS:Sixty male Wistar rats were randomly divided into 5 groups: sham surgery, model control, astragaloside (150 mg•kg•d), low- and high-dose SHT (1.5 and 3.0 g•kg•d, repectively) groups. One week after drug treatment, rats underwent surgery to establish the IRI models. At 24 h and 72 h after the modeling, serum creatinine (Scr) and blood urea nitrogen (BUN) were analyzed; pathological damage were scored after periodic acid-Schiffstaining. TLR2, TLR4 and myeloid differentiation factor 88 (MyD88) protein and mRNA expressions were detected by inmmunohistochemistry, Western blot and qPCR. Tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) protein expressions were detected by enzyme linked immunosorbent assay.
RESULTS:Compared with the sham group, the model group exhibited severe change in renal function (Scr: 189.42±21.50, P<0.05), pathological damage (damage score: 4.50±0.55, P<0.05), and the expression levels of TLR2, TLR4, MyD88, TNF-α, IL-6 were significantly higher than other groups. Meanwhile, the levels of TLRs in model group showed upward tendency from 24 to 72 h, unparalleled with pathological and functional changes. The aforementioned parameters were alleviated to a certain extent, and, in addition to TLRs, presented the obvious downward trending from the 24 to 72 h after the intervention in the SHT and astragaloside groups relative to the model (P<0.05); in particular, the most significant mitigation of these changes was observed in the SHT-H group (P<0.05).
CONCLUSION:TLRs may be an important spot to treat and research in acute kidney injury. SHT could effectively mitigate renal injuries and promote recovery of IRI injuries through suppression of degeneration induced by up-regulation of TLR2 and TLR4 expression levels in the MyD88-dependent signaling pathway and exhibit some dose dependence.
